TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07890714: A Phase 1/2, Multicenter, Master Protocol Trial to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) in Participants With Solid Tumors (TROPION-PanTumor04)

Sponsor: Daiichi Sankyo · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 268 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07890714 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07890714 Rescue Dossier →